Software Giant's Shares Plunge 65% Despite Enterprise Growth Surge
A leading software company has faced a turbulent year, with shares plummeting by nearly 65% over the past twelve months. Despite this downturn, the firm reported strong growth in its enterprise segment, driven by a record U.S. deal. Management remains focused on innovation and strategic adjustments as challenges persist.
The company's annual report for 2025 highlighted a mixed performance across its business segments. While revenue from its traditional SMB division dipped slightly, the core enterprise segment surged by 19%, boosted by a major U.S. contract. Annual recurring revenue (ARR) in this area also climbed by 11%, reaching €241 million.
However, setbacks from the 2024 acquisition of British software firm 1E continue to weigh on operations. Disruptions and the loss of key personnel have slowed integration, with an expected one-time customer loss of around €8 million in early 2026. The churn rate also rose to 16.4% in the fourth quarter, a trend forecast to last until mid-2026.
Looking ahead, the company projects flat to modest revenue growth of 0% to 3% for 2026, adjusted for currency effects. Its adjusted EBITDA margin is expected to remain strong at roughly 43%. Management is advancing product innovations, including deeper integrations with Microsoft Intune and a new partnership with Cybus for augmented reality solutions. Additionally, the firm is set to transition from the MDAX to the SDAX, prompting index-tracking funds to adjust their holdings.
Since Volkswagen's strategic realignment in 2023, the company's position in the software sector has improved relative to competitors. This progress is reflected in forward-looking statements within the 2025 report.
The company's shares recently hit a 52-week low of €4.48, underscoring investor concerns. Yet, its enterprise growth and innovation pipeline suggest resilience in key areas. The upcoming shift to the SDAX and ongoing operational challenges will likely shape its trajectory in the months ahead.
Read also:
- Federal Funding Supports Increase in Family Medicine Residency Program, Focusing on Rural Health Developments
- Potential Role of DHA in Shielding the Brain from Saturated Fats?
- Alternative Gentle Retinoid: Exploring Bakuchiol Salicylate for Sensitive Skin
- Hanoi initiates a trial program for rabies control, along with efforts to facilitate the transition from the dog and cat meat trade industry.
